Glaukos Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Glaukos Corp Company

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Glaukos Corp Info



Ticker SymbolGKOS

Company nameGlaukos Corp

IPO dateJun 25, 2015

CEOMr. Thomas William Burns

Number of employees995

Security typeOrdinary Share

Fiscal year-endJun 25

Address1 Glaukos Way

CityALISO VIEJO

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code92656

Phone19493679600

Websitehttps://www.glaukos.com

Ticker SymbolGKOS

IPO dateJun 25, 2015

CEOMr. Thomas William Burns

Company Executives of Glaukos Corp



Name

Name/Position

Position

Shareholding

Change

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.51M

+0.69%

Mr. David F. Hoffmeister

Independent Director

69.52K

+56.16%

Mr. Mark J. Foley

Lead Independent Director

56.36K

+3.89%

Ms. Aimee S. Weisner, J.D.

Independent Director

49.23K

+4.47%

Mr. Marc A. Stapley

Independent Director

36.18K

+6.19%

Dr. Tomas Navratil

Chief Development Officer

33.32K

-12.37%

Dr. Leana S. Wen, M.D.

Independent Director

--

Dr. Gilbert H. (Gil) Kliman, M.D.

Independent Director

--

Ms. Denice M. Torres, J.D.

Independent Director

--

Mr. Joseph E. Gilliam

President, Chief Operating Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Thomas William Burns

Chairman of the Board, Chief Executive Officer

1.51M

+0.69%

Mr. David F. Hoffmeister

Independent Director

69.52K

+56.16%

Mr. Mark J. Foley

Lead Independent Director

56.36K

+3.89%

Ms. Aimee S. Weisner, J.D.

Independent Director

49.23K

+4.47%

Mr. Marc A. Stapley

Independent Director

36.18K

+6.19%

Dr. Tomas Navratil

Chief Development Officer

33.32K

-12.37%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Glaucoma

103.53M

83.41%

Corneal Health

20.59M

16.59%

By RegionUSD

Name

Revenue

Proportion

United States

90.52M

72.93%

International

33.60M

27.07%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Glaucoma

103.53M

83.41%

Corneal Health

20.59M

16.59%

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

13.75%

The Vanguard Group, Inc.

10.50%

Fidelity Management & Research Company LLC

9.12%

Wellington Management Company, LLP

5.65%

State Street Investment Management (US)

3.64%

Other

57.34%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

13.75%

The Vanguard Group, Inc.

10.50%

Fidelity Management & Research Company LLC

9.12%

Wellington Management Company, LLP

5.65%

State Street Investment Management (US)

3.64%

Other

57.34%

Shareholder Types

Shareholders

Proportion

Investment Advisor

56.75%

Investment Advisor/Hedge Fund

34.75%

Hedge Fund

9.08%

Individual Investor

3.32%

Pension Fund

2.06%

Research Firm

1.76%

Sovereign Wealth Fund

1.32%

Bank and Trust

1.12%

Family Office

0.04%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

653

61.34M

106.80%

+235.97K

2025Q2

638

61.06M

106.48%

+15.37K

2025Q1

643

60.20M

105.40%

-1.30M

2024Q4

610

59.75M

105.65%

+533.86K

2024Q3

567

57.47M

104.31%

-894.95K

2024Q2

545

56.86M

103.79%

-713.22K

2024Q1

509

54.47M

110.12%

-1.91M

2023Q4

480

53.71M

109.34%

-1.79M

2023Q3

475

52.90M

108.58%

-1.85M

2023Q2

486

51.69M

106.83%

-2.99M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

7.90M

13.77%

+252.68K

+3.31%

Jun 30, 2025

The Vanguard Group, Inc.

6.10M

10.63%

+146.00K

+2.45%

Jun 30, 2025

Fidelity Management & Research Company LLC

5.24M

9.14%

-327.70K

-5.89%

Jun 30, 2025

Wellington Management Company, LLP

3.24M

5.66%

+953.61K

+41.63%

Jun 30, 2025

State Street Investment Management (US)

2.09M

3.64%

+105.97K

+5.34%

Jun 30, 2025

PRIMECAP Management Company

1.83M

3.19%

+609.52K

+50.02%

Jun 30, 2025

Burns (Thomas William)

1.51M

2.63%

+10.26K

+0.69%

Sep 23, 2025

Geode Capital Management, L.L.C.

1.33M

2.32%

+115.53K

+9.51%

Jun 30, 2025

AllianceBernstein L.P.

1.25M

2.18%

-25.68K

-2.01%

Jun 30, 2025

Westfield Capital Management Company, L.P.

1.17M

2.04%

+83.67K

+7.72%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Invesco S&P SmallCap Health Care ETF

2.97%

Alger Weatherbie Enduring Growth ETF

1.88%

SPDR S&P Health Care Equipment ETF

1.53%

ROBO Global Healthcare Technology & Innovation ETF

1.31%

Vanguard S&P Small-Cap 600 Growth Index Fund

0.63%

SPDR S&P 600 Small Cap Growth ETF

0.63%

iShares S&P Small-Cap 600 Growth ETF

0.59%

iShares U.S. Medical Devices ETF

0.57%

SPDR S&P SmallCap 600 ESG ETF

0.46%

OneAscent Small Cap Core ETF

0.46%

Invesco S&P SmallCap Health Care ETF

Proportion2.97%

Alger Weatherbie Enduring Growth ETF

Proportion1.88%

SPDR S&P Health Care Equipment ETF

Proportion1.53%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.31%

Vanguard S&P Small-Cap 600 Growth Index Fund

Proportion0.63%

SPDR S&P 600 Small Cap Growth ETF

Proportion0.63%

iShares S&P Small-Cap 600 Growth ETF

Proportion0.59%

iShares U.S. Medical Devices ETF

Proportion0.57%

SPDR S&P SmallCap 600 ESG ETF

Proportion0.46%

OneAscent Small Cap Core ETF

Proportion0.46%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data